Revvity (NYSE:RVTY) Stock Rating Upgraded by UBS Group

Revvity (NYSE:RVTY) was upgraded by UBS Group from a “neutral” rating to a “buy” rating in a research report issued to clients and investors on Thursday, Marketbeat.com reports. The brokerage currently has a $115.00 target price on the stock, down from their previous target price of $145.00. UBS Group’s price objective suggests a potential upside of 22.29% from the company’s current price.

A number of other equities analysts have also recently weighed in on the company. Raymond James reiterated an “outperform” rating and set a $120.00 price target (down from $145.00) on shares of Revvity in a report on Tuesday. Robert W. Baird dropped their price objective on Revvity from $127.00 to $125.00 and set an “outperform” rating for the company in a research note on Tuesday. Sanford C. Bernstein lowered shares of Revvity from an “outperform” rating to a “market perform” rating and set a $130.00 price target on the stock. in a research note on Friday, January 10th. The Goldman Sachs Group decreased their price target on shares of Revvity from $140.00 to $125.00 and set a “buy” rating for the company in a research report on Tuesday. Finally, JPMorgan Chase & Co. reduced their price objective on Revvity from $120.00 to $100.00 and set a “neutral” rating on the stock in a research note on Tuesday. Four investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Revvity presently has a consensus rating of “Moderate Buy” and an average target price of $125.64.

Revvity Trading Up 1.2 %

Shares of NYSE:RVTY opened at $94.04 on Thursday. The business has a 50 day moving average of $102.80 and a two-hundred day moving average of $112.12. Revvity has a 12-month low of $88.53 and a 12-month high of $129.50. The company has a market capitalization of $11.30 billion, a PE ratio of 42.55, a PEG ratio of 3.82 and a beta of 1.07. The company has a current ratio of 3.60, a quick ratio of 3.03 and a debt-to-equity ratio of 0.41.

Revvity (NYSE:RVTY) last issued its quarterly earnings data on Monday, April 28th. The company reported $1.01 EPS for the quarter, beating the consensus estimate of $0.96 by $0.05. The company had revenue of $664.76 million for the quarter, compared to analyst estimates of $662.30 million. Revvity had a return on equity of 7.68% and a net margin of 9.81%. Revvity’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same period last year, the company earned $0.98 earnings per share. As a group, analysts forecast that Revvity will post 4.94 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Assetmark Inc. raised its position in Revvity by 3,700.0% during the fourth quarter. Assetmark Inc. now owns 266 shares of the company’s stock worth $30,000 after acquiring an additional 259 shares during the last quarter. Optiver Holding B.V. acquired a new stake in shares of Revvity during the fourth quarter valued at $33,000. Quarry LP raised its stake in Revvity by 45.7% in the 4th quarter. Quarry LP now owns 303 shares of the company’s stock valued at $34,000 after purchasing an additional 95 shares during the last quarter. Millstone Evans Group LLC acquired a new stake in shares of Revvity during the 4th quarter worth about $38,000. Finally, Vermillion Wealth Management Inc. purchased a new position in shares of Revvity during the fourth quarter valued at approximately $41,000. Hedge funds and other institutional investors own 86.65% of the company’s stock.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.